|Bid||12.09 x 1100|
|Ask||12.10 x 1100|
|Day's Range||11.91 - 12.31|
|52 Week Range||8.27 - 16.82|
|Beta (3Y Monthly)||1.78|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Amicus Therapeutics (FOLD) today announced two new additions to the Senior Leadership Team. Jill Weimer, PhD, a developmental neuroscientist and recognized thought leader in the field of neurologic rare disease gene therapy science, has joined as Senior Vice President of Discovery Research and Gene Therapy Science.
CRANBURY, N.J., June 04, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced the closing of its previously announced offering of common stock. The Company issued a total.
CRANBURY, N.J., June 03, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following scientific and investor conferences in June..
Amicus Therapeutics (FOLD) today announced the pricing of an underwritten offering of 16,279,070 shares of its common stock at $10.75 per share. The gross proceeds from the offering to Amicus are expected to be $175 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,441,860 shares of its common stock.
Amicus Therapeutics (FOLD) today announced it has commenced a $150 million underwritten public offering of its common stock. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and SVB Leerink LLC are acting as joint book-running managers for the proposed offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering.
Exclusive Disease-Specific Worldwide Rights to Penn’s Next Generation Gene Therapy Technologies from the Wilson Lab for the Majority of Lysosomal Disorders Current.
Amicus Therapeutics (FOLD) today announced the election and appointment of Burke W. Whitman to its Board of Directors, effective at the end of this quarter. Mr. Whitman is a proven leader of corporate and military organizations. He has served as a corporate CEO, CFO and board member of multiple publicly-traded and Fortune 500 healthcare service companies, as well as the commanding general of the 4th Marine Division and the commander of Marine Forces Reserve. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “On behalf of our Board of Directors, I am pleased to announce Burke Whitman’s appointment to the Amicus Board.
CRANBURY, N.J., May 10, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside.
1Q19 Galafold® (migalastat) Strong Launch Trends Continue with Largest Quarterly Number of Net New Patients Added Globally (150+ Net New Galafold Patients in 1Q19) 1Q19.
Amicus Therapeutics (FOLD) today announced initial preclinical data from its investigational adeno-associated viral (AAV) gene therapy program for Pompe disease in mice. Pompe disease is an inherited lysosomal storage disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA).
CRANBURY, N.J., April 25, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 8,.
CRANBURY, N.J., April 15, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced the company will present initial preclinical data from its investigational adeno-associated.
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Amicus Therapeutics (FOLD) today announced that the United States Patent and Trademark Office has issued two new patents directed to the composition of matter and methods of making ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly mannose-6 phosphate (M6P), to enhance uptake. ATB200 is the biologic component of the Company’s investigational Pompe treatment paradigm AT-GAA, which consists of ATB200 co-administered with AT2221, a pharmacological chaperone.
Continued Strong Galafold Launch Trends in Early 2019 - On Track to Achieve FY19 Revenue Guidance of $160M-$180M FY18 Galafold Revenue of $91.2M Reflects 650+ Fabry Patients.
NEW YORK, NY / ACCESSWIRE / February 28, 2019 / Amicus Therapeutics, Inc. (NASDAQ: FOLD ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 28, 2019 ...
Amicus Therapeutics (FOLD) today announced it is establishing a new Global Research and Gene Therapy Center of Excellence in uCity Square in Philadelphia, PA, to advance its commitment to world-class science that makes a meaningful difference in the lives of people living with rare metabolic diseases. Philadelphia is a well-regarded ecosystem for biotechnology and gene therapy research and offers an ideal environment for Amicus to advance its pipeline, attract and retain top talent and foster external collaborations within the rare diseases.
Amicus Therapeutics (FOLD) today announced that the U.S. Food and Drug Administration (FDA) has granted to Amicus a Breakthrough Therapy Designation (“BTD”) to AT-GAA for the treatment of late onset Pompe disease, an inherited lysosomal storage disorder caused by the deficiency of an enzyme known as acid alpha-glucosidase (GAA). AT-GAA is the first ever investigational product for Pompe disease to receive BTD.
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
CRANBURY, N.J., Feb. 12, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February.
Amicus Therapeutics (FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme deficiency that leads to accumulation of glycogen (disease substrate) in cells. Patients treated with AT-GAA for up to 24 months showed improvements in six-minute walk test (6MWT) distance and other measures of motor function and muscle strength, stability or increases in forced vital capacity (FVC), and durable reductions in biomarkers of muscle damage and disease substrate. An additional poster2 with detailed results for the non-ambulatory cohort in the ATB200-02 study is also part of this afternoon’s poster session.
NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb. ...
CRANBURY, N.J., Jan. 18, 2019 -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare.
NEW YORK, NY / ACCESSWIRE / January 16, 2019 /U.S. markets rose on Tuesday as Netflix helped push the tech sector higher after announcing it would raise the price of its monthly membership. Tech giants ...
NEW YORK, Jan. 10, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.